1-3 of 3
Erika J Martin, MT(ASCP)
Close
Sort by
Journal Articles

Characterizing the Effects of NN1731 and rFVIIa In Severe Hemophilia Patients with a Poor Laboratory Response to In Vivo Dosing of rFVIIa 90 μ g/Kg

Donald F Brophy, Pharm.D., Erika J Martin, MT(ASCP), John Christian Barrett, MD, Jan G Kuhn, RN, Melinda Nolte, RN, Ulla Hedner, MD, PhD, Mirella Ezban, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 4414.
https://doi.org/10.1182/blood.V116.21.4414.4414
Published: 2010
Journal Articles

Evaluation of Clotting Parameters in a Patient with Hemophilia A and Inhibitors Who Has a Poor Clinical Response to Standard Dose rFVIIa.

Marcus E. Carr, Jr., MD, PhD, Erika J Martin, MT(ASCP), John Christian Barrett, MD, Mindy Nolte, RN, Janice Kuhn, RN, Mirella Ezban, PhD, Ulla Hedner, MD, PhD, Donald Brophy
Journal: Blood
Blood (2009) 114 (22): 4440.
https://doi.org/10.1182/blood.V114.22.4440.4440
Published: 2009
Journal Articles

Differential Dose Dependent Effects of Recombinant FVIIa and Enhanced Activity Analogue (NN1731) on Thrombin Generation, Platelet Function and Clot Structure in Blood from Normal Volunteers and Patients with Factor VIII Deficiency with or without Factor VIII Inhibitor Antibodies.

Donald F. Brophy, PharmD, Erika J. Martin, MT(ASCP), Melinda Nolte, R.N., Jan G. Kuhn, R.N., MPH, Sashidhar N. Reddy, MD, Mirella Ezban, MD, Marcus E. Carr, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 4033.
https://doi.org/10.1182/blood.V106.11.4033.4033
Published: 2005